PROF stock · REGN stock

PROF vs REGN

Profound Medical Corp (PROF) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.

Profound Medical Corp (PROF) is a medical devices company listed on NASDAQ.

Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.

Latest reported PROF revenue for 2024-12-31 was $10.7M. Net income was -$27.8M. Revenue was up 48.4% from 2023-12-31 to 2024-12-31. PROF currently screens at market cap $238.7M.

Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.

PROF currently screens at market cap $238.7M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.

Not investment advice. Open the PROF and REGN stock pages for the full models.

Not investment advice.

Popular Stock Comparisons